.Pharmacolibrary.Drugs.ATC.B.B01AE07

Information

Dabigatran etexilate is an oral direct thrombin inhibitor used for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for treatment and prevention of deep vein thrombosis and pulmonary embolism. It is approved and widely used today as a novel oral anticoagulant (NOAC).

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, following a single oral dose.

References

1. Stangier, J, & Clemens, A (2009). Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 15 Suppl 1 9S–16S. DOI:10.1177/1076029609343004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19696042

2. Stangier, J (2008). Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical pharmacokinetics 47(5) 285–295. DOI:10.2165/00003088-200847050-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18399711

3. Duan, J, et al., & Harada, A (2020). Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. European journal of drug metabolism and pharmacokinetics 45(5) 601–609. DOI:10.1007/s13318-020-00626-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32474728

Revisions

• 06/2025 initial generated model